Immunic Secures $200M Upfront in Oversubscribed Private Placement, Initiates CEO Search for Commercial Leader

summarizeSummary

Immunic, Inc. announced a highly dilutive but critical private placement raising $200 million upfront, with potential for an additional $200 million, to fund clinical trials and extend its cash runway to late 2027. The company will also pursue a reverse stock split and transition its CEO to a scientific role, initiating a search for a new commercial leader.

check_boxKey Events

• Secured $200M Upfront Capital

  Immunic entered a private placement to issue pre-funded warrants and common warrants for $200 million in gross proceeds, with potential for an additional $200 million upon common warrant exercise. The offering was priced at $0.873 per unit.

• Extended Cash Runway

  The financing is expected to fund operating and capital expenditures to late 2027, supporting clinical trials and operations.

• Planned Reverse Stock Split

  The company will seek stockholder approval for a reverse stock split of at least 10:1, likely to address Nasdaq listing requirements, following a previous transfer to the Nasdaq Capital Market on 2026-01-06.

• CEO Transition & Leadership Changes

  CEO Daniel Vitt will transition to a scientific strategy role, and a search for a new commercial CEO has begun. Simona Skerjanec was appointed Interim Chairperson, and Thor Nagel (BVF Partners L.P.) joined the Board, while Maria Törnsén resigned.

auto_awesomeAnalysis

Immunic, Inc. has secured a substantial capital injection of $200 million upfront, with potential for an additional $200 million, through a private placement. This financing, significantly larger than the company's market capitalization, is critical for funding ongoing and planned clinical trials, including the Phase 3 ENSURE trials for relapsing multiple sclerosis and a new Phase 3 program for primary progressive multiple sclerosis. The proceeds are expected to extend the company's cash runway to late 2027, addressing immediate liquidity concerns. The offering was priced at a discount to the current market price ($0.873 per unit vs. current stock price of $0.95), and the company plans a reverse stock split, which are typically negative signals but appear necessary to secure this vital funding and maintain Nasdaq listing. Strategically, CEO Daniel Vitt will transition to a scientific role, and a search for a commercially-focused CEO has begun, signaling a pivot towards potential commercialization. The appointment of a new interim Chairperson and a director from a lead investor further strengthens governance and investor alignment.